Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915589 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01915589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01915589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
September 16, 2013
Completion date
October 8, 2014
Enrollment
16 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular